leucovorin calcium / Generic mfg. 
Welcome,         Profile    Billing    Logout  
 424 Diseases   807 Trials   807 Trials   14372 News 


«12...2627282930313233343536...235236»
  • ||||||||||  5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., irinotecan / Generic mfg.
    A Chemoresistance Signature to Predict FOLFIRINOX Sensitivity in Pancreatic Adenocarcinoma () -  Dec 29, 2023 - Abstract #SSO2024SSO_412;    
    In addition, our findings support targeting the G2M checkpoint and E2F pathways to potentially counteract FFX resistance in PDAC patients. Learning Objectives: Upon completion, participant will be able to understand the need for improving chemotherapy treatment strategies for pancreatic cancer.
  • ||||||||||  5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., irinotecan / Generic mfg.
    Highly Sensitive Low Input Methylated Digital Droplet PCR Assay for Pancreatic Adenocarcinoma Molecular Subtyping () -  Dec 29, 2023 - Abstract #SSO2024SSO_408;    
    ddPCR is a powerful, high sensitivity, lower cost technology offering clinical promise for the early detection and disease monitoring for many cancers, and it is already FDA approved for CML treatment response monitoring. Here we show our ability to predict subtype using only 14 nanograms of DNA on a ddPCR platform, >10 fold less required than Nanostring and >70 fold less than RNA sequencing.
  • ||||||||||  5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., irinotecan / Generic mfg.
    Combination of tumor and CAF subtypes better predict response to neoadjuvant therapy in pancreatic cancer () -  Dec 29, 2023 - Abstract #SSO2024SSO_401;    
    Better locoregional response to systemic therapy may lead to better overall survival in these subtypes. Molecular subtyping of PDAC for both the tumor and tumor microenvironment may be important steps in selecting first-line therapy for patients with this deadly disease.
  • ||||||||||  Enrollment closed, Trial completion date, Trial primary completion date:  Neoadjuvant RCT Versus CT for Patients With Locally Advanced, Potentially Resectable Adenocarcinoma of the GEJ (clinicaltrials.gov) -  Dec 26, 2023   
    P3,  N=342, Active, not recruiting, 
    Further studies are needed to confirm these findings and to identify the optimal chemotherapy regimen for this patient population. Recruiting --> Active, not recruiting | Trial completion date: Aug 2028 --> Dec 2025 | Trial primary completion date: May 2028 --> Dec 2025
  • ||||||||||  5-fluorouracil / Generic mfg.
    Journal:  5-Fluorouracil-associated severe hypertriglyceridaemia with positive rechallenge. (Pubmed Central) -  Dec 24, 2023   
    We here report the case of a patient who developed 5-FU-associated grade 4 HTG with TG level raising up to 37.1?mmol/L (3286?mg/dL) occurring after the ninth cycle of adjuvant FOLFOX (Fluorouracil and Oxaliplatin) chemotherapy...Chemotherapy was therefore permanently stopped. Approximately 8 weeks after chemotherapy discontinuation, TG fell back to range at 2.1?mmol/L (189?mg/dL) allowing interruption of fenofibrate without HTG recurrence at 3 months.
  • ||||||||||  leucovorin calcium / Generic mfg.
    Journal:  Cerebral folate deficiency: a treatable cause of late deterioration in epilepsy with developmental delay. (Pubmed Central) -  Dec 23, 2023   
    Following antiseizure medication adjustment and treatment with folinic acid, she stabilised with improved seizure control and limited improvement in language and motor function; she has remained neurologically stable for more than a decade...Metabolic conditions are less well recognised in adults and can be under-diagnosed. They are potentially treatable and should be considered even in the presence of another cause, particularly when the presentation is not fully compatible.
  • ||||||||||  5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., irinotecan / Generic mfg.
    Journal:  Precision medicine for KRAS wild-type pancreatic adenocarcinomas. (Pubmed Central) -  Dec 22, 2023   
    KRAS patients display distinct disease characteristics and outcomes with prolonged overall survival. KRAS patients also harbor more actionable molecular alterations, leading to higher survival rates after receiving molecularly matched treatments.
  • ||||||||||  Onivyde (nanoliposomal irinotecan) / Servier, Ipsen
    Trial primary completion date, Metastases:  NAPOLI-2: Fluorouracil, Leucovorin, and Nanoliposomal Irinotecan in Biliary Cancer (clinicaltrials.gov) -  Dec 21, 2023   
    P2,  N=44, Recruiting, 
    Recruiting --> Active, not recruiting | Trial completion date: Dec 2024 --> Dec 2025 | Trial primary completion date: Dec 2023 --> Dec 2024 Trial primary completion date: Nov 2023 --> May 2024
  • ||||||||||  Graspa (eryaspase) / PHAXIAM Therap
    Trial completion date:  Eryaspase With Modified FOLFIRINOX in Advanced Pancreatic Ductal Adenocarcinoma (clinicaltrials.gov) -  Dec 20, 2023   
    P1,  N=19, Active, not recruiting, 
    A randomized or prospective trial will be required to further prove these data and explore its potentiality, especially if compared to conventional treatment. Trial completion date: Dec 2023 --> Jul 2024
  • ||||||||||  5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., irinotecan / Generic mfg.
    Immuno-molecular modulation in pancreatic cancer following isotoxic high-dose stereotactic body radiotherapy (iHD-SBRT). (Teun - Hilton Antwerp Old Town) -  Dec 19, 2023 - Abstract #BWG2024BWG_177;    
    Methods Paraffin-embedded residual tumoral tissues of 50 localized PDAC resected between 2011 and 2020 were used: seventeen patients had surgery first, seventeen received an induction chemotherapy with FOLFIRINOX (FFX) only and sixteen with FFX followed by an iHD-SBRT designed to individually maximize the dose prescribed to the tumor and vessels interfaces up to Dmax(0.5cc)<lt;53Gy in 5 fractions...Despite an increase in collagen deposit, the global lymphocyte infiltration is preserved after iHD-SBRT. We also identified several increased pro-tumoral cells and pathways after iHD-SBRT that could improve the development of better-oriented combination trials involving high-dose SBRT.
  • ||||||||||  5-fluorouracil / Generic mfg.
    Journal, Surgery, Metastases:  Nationwide Use and Outcome of Surgery for Locally Advanced Pancreatic Cancer Following Induction Chemotherapy. (Pubmed Central) -  Dec 18, 2023   
    Resection of LAPC following chemo(radio)therapy is infrequently performed in the Netherlands, albeit with acceptable morbidity, mortality, and OS. Given these findings, a structured nationwide approach involving international centers of excellence would be needed to improve selection of patients with LAPC for surgical resection following induction therapy.
  • ||||||||||  lunresertib (RP-6306) / Repare Therap
    Trial completion date, Trial primary completion date:  RP-6306 in Patients With Advanced Cancer (clinicaltrials.gov) -  Dec 15, 2023   
    P2,  N=78, Recruiting,